About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Zevalin Post-marketing Surveillance in Japan

NCT01448928·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Spectrum Pharmaceuticals, Inc

With

Bayer

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients who received Zevalin for relapsed or refractory:
CD20+
low grade B-cell non-Hodgkin's lymphoma
Mantle cell lymphoma

You may not be if

Patients who are contraindicated based on the product label

The record

StatusCompleted

PhaseNo phase

Taking part400

StartedSep 2008

UpdatedOct 1, 2021

Conditions

Non-Hodgkin's Lymphoma (NHL)

Where1

Multiple Locations, Japan

Clareo Health | Zevalin Post-marketing Surveillance in Japan